| 查看: 7412 | 回复: 32 | |||
| 当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖 | |||
[交流]
埃索美拉唑钠 药典标准
|
|||
|
埃索美拉唑钠 有没有药典标准呀 一直没找到... 没有的话,自己生产的话这标准是参考 埃索美拉唑镁 还是 奥美拉唑钠 |
» 本帖已获得的红花(最新10朵)
» 猜你喜欢
二乙烯基砜的合成路径
已经有4人回复
求一株[b]敲除MTAP(human)的HCT-116(人结肠癌细胞)/b]细胞
已经有0人回复
药理学论文润色/翻译怎么收费?
已经有78人回复
求助!求美国食品化学药典内容:FCC13【低聚果糖专论】
已经有0人回复
【2027博士申请】纳米药物递送方向
已经有5人回复
消耗微量API,便可预测早期研发阶段的HME工艺可行性
已经有0人回复
反应液中苯酐除去
已经有1人回复
» 本主题相关价值贴推荐,对您同样有帮助:
埃索美拉唑钠原料的开发
已经有16人回复
埃索美拉唑钠的重结晶方法
已经有18人回复
求助埃索美拉唑钠的研发背景资料
已经有8人回复
埃索美拉唑镁肠溶微丸释放时变色
已经有13人回复
大家有没有做埃索美拉唑钠项目的进来交流一下!
已经有47人回复
【求助】高手请进 关于埃索美拉唑钠盐的紫外图谱
已经有8人回复
【求助】埃索美拉唑钠
已经有17人回复
» 抢金币啦!回帖就可以得到:
云南大学丁军桥团队2027年博士招生
+1/805
【征稿中!】2026年机械、制造技术与材料国际会议 (MEMTM 2026)
+1/616
南京大学医学院附属鼓楼医院 肿瘤疫苗与纳米医学团队 博士后招聘
+1/91
山东大学晶体材料全国重点实验室招收2027年锂金属电池负极材料博士一名
+1/85
江西理工大学稀土学院博士招聘(安家费启动金等合计超100w)
+1/85
上海交通大学周宝文课题组招收2027年申请考核制博士研究生
+1/83
2027级博士研究生——质谱分析
+5/80
湖南大学电镜中心招收2027年推免直博生
+1/66
深圳大学刘翼振课题组诚聘博士后(CRISPR分子诊断)
+1/50
香港城市大学分子电子学方向招收2027年夏季和秋季入学博士生
+1/45
以色列理工-生物质、塑料等催化转化2-3名---全奖博士研究生(随时入学)和科研助理
+1/19
评职称需要,卖发明专利了:D有技术储备需求的设备厂商可联系
+1/18
神经生物学,基础医学,科研助理招聘
+1/15
天津大学浙江研究院2026年第二批招聘公告:高分子等方向特聘青年研究员/博士后
+1/13
新加坡国立大学Sibudjing Kawi教授课题组招聘博士后(热催化/等离子体催化方向)
+1/8
深圳理工大学罗伟课题组招收博士研究生-第一性原理-机器学习-铁电-拓扑方向(1名)
+1/6
石蜡切片VS冰冻切片:哪种更适合免疫荧光检测?
+1/6
深圳大学岩土多场耦合课题组-长期招聘研究生、博士后、专职研究人员
+1/4
苦寻-西安交通大学统计学同学
+1/2
义翘神州推出全长p-Tau217蛋白,助力阿尔茨海默病下一代生物标志物检测开发
+1/2
10楼2011-08-31 11:31:06
2楼2011-08-30 14:35:50
★
hao8431(金币+1):谢谢参与
hao8431(金币+1):谢谢参与
|
以下是USP34版友原料药镁盐的标准 Esomeprazole Magnesium (es'' oh mep' ra zole mag nee' zee um). C34H36MgN6O6S2·3H2O Trihydrate: 767.17 C34H36MgN6O6S2 Anhydrous: 713.12 1H-Benzimidazole,5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl], magnesium salt (2:1), trihydrate; 5-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole, magnesium salt (2:1), trihydrate [217087-09-7]. DEFINITION Esomeprazole Magnesium contains NLT 98.0% and NMT 102.0% of C34H36MgN6O6S2, calculated on the anhydrous basis. IDENTIFICATION • A. INFRARED ABSORPTION 197K • B. The Sample solution, prepared and tested as directed in the test for Content of Magnesium, exhibits a significant absorption at 285.2 nm. ASSAY • PROCEDURE Solution A: Dissolve 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Solution B: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 100 mL. Mobile phase: Acetonitrile and Solution A (7:13) Standard solution: Transfer 10 mg of USP Omeprazole RS to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of omeprazole. ] Sample solution: Transfer 10 mg of Esomeprazole Magnesium to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of esomeprazole magnesium. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 1 mL/min Injection size: 20 μL System suitability Sample: Standard solution Suitability requirements Column efficiency: NLT 2000 theoretical plates Relative standard deviation: NMT 2.0% Analysis Samples: Standard solution and Sample solution Calculate the percentage of C34H36MgN6O6S2 in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × (CS/CU) × [Mr1/(2 × Mr2)] × 100 Acceptance criteria: 98.0%–102.0% on the anhydrous basis OTHER COMPONENTS • CONTENT OF MAGNESIUM Lanthanum solution: Transfer 58.7 g of lanthanum oxide into a 1000-mL volumetric flask, wet the substance with some water, and dissolve by cautious addition of 250 mL of hydrochloric acid in 20- to 30-mL portions, cooling between the additions. Add water while stirring, cool to room temperature, and dilute with water to volume. [NOTE—Store the solution in a plastic bottle. ] Standard stock solution: 1000 μg/mL of magnesium in water, from a commercially prepared atomic absorption standard solution. [NOTE—Store the solution in a plastic bottle. ] Standard solution A: Transfer 10.0 mL of Standard stock solution to a 500-mL volumetric flask, add 50 mL of 1 N hydrochloric acid, and dilute with water to volume. Transfer 20.0 rU = = peak response from the Sample solution rS = = peak response from the Standard solution CS = = concentration of omeprazole in the Standard solution (mg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (mg/mL) Mr1 = = molecular weight of esomeprazole magnesium, 713.12 Mr2 = = molecular weight of omeprazole, 345.42 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. [NOTE— This solution contains 2 μg/mL of magnesium. ] Standard solution B: Combine 5.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.1 μg/mL). Standard solution C: Combine 10.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.2 μg/mL). Standard solution D: Combine 15.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.3 μg/mL). Standard solution E: Combine 20.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.4 μg/mL). Standard solution F: Combine 25.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.5 μg/mL). [NOTE—Concentrations of the Standard solutions and the Sample solution may be modified to fit the linear or working range of the instrument. When using instruments with a linear calibration graph, the number of Standard solutions can be reduced. ] Blank solution: Transfer 4.0 mL of Lanthanum solution to a 100-mL volumetric flask, and dilute with water to volume. Sample solution: Transfer 250 mg of Esomeprazole Magnesium to a 100-mL volumetric flask, add 20 mL of 1 N hydrochloric acid, swirl until dissolved, and dilute with water to volume. Allow to stand for 30 min. Transfer 10.0 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. Transfer 10.0 mL of the solution to another 100-mL volumetric flask, add 4.0 mL of Lanthanum solution, and dilute with water to volume. Spectrometric conditions (See Spectrophotometry and Light-Scattering 851 .) Mode: Atomic absorption spectrophotometer Flame: Air–acetylene Analytical wavelength: 285.2 nm Analysis Samples: Standard solution B, Standard solution C, Standard solution D, Standard solution E, Standard solution F, Blank solution, and Sample solution Determine the concentration, Cs, in μg/mL, of magnesium in the Sample solution using the calibration graph. Calculate the percentage of magnesium in the portion of Esomeprazole Magnesium taken: Result = (CS/CU) × (100/(100 F)) × 100 CS = = content of magnesium in the Sample solution as calculated above (μg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (μg/mL) F = = content of water in Esomeprazole Acceptance criteria: 3.30%–3.55%, on anhydrous basis IMPURITIES Organic Impurities • PROCEDURE 1 Solution A: 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Mobile phase: Acetonitrile and Solution A (11:29). [NOTE—To improve the resolution, the composition may be changed to 1:3, if necessary. ] System suitability solution: 1 mg of USP Omeprazole RS and 1 mg of USP Omeprazole Related Compound A RS in 25 mL of Mobile phase. [NOTE—Omeprazole Related Compound A is omeprazole sulfone. ] Sample solution: 4 mg of Esomeprazole Magnesium in 25 mL of Mobile phase. [NOTE— Prepare this solution fresh. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 0.8–1 mL/min Injection size: 50 μL System suitability Sample: System suitability solution [NOTE—For relative retention times, see Impurity Table 1. ] Suitability requirements Resolution: NLT 3 between omeprazole related compound A and omeprazole Analysis Sample: Sample solution Record the chromatogram for at least 4.5 times the retention time of the omeprazole peak, and measure the peak responses. Identify the impurities based on the retention times shown in Impurity Table 1. Calculate the percentage of any individual impurity in the portion of Esomeprazole Magnesium taken: Result = (rU/rT) × 100 Magnesium, as determined in Specific Tests, Water Determination (%) rU = = peak response for each impurity = = sum of all peak responses Acceptance criteria Individual impurities: See Impurity Table 1. Total impurities: NMT 0.5% Impurity Table 1 • PROCEDURE 2: ENANTIOMERIC PURITY Solution A: Mix 70 mL of 1 M monobasic sodium phosphate with 20 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. Diluent: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Mobile phase: Acetonitrile and Solution A (3:17) System suitability solution: 2 mg of USP Omeprazole RS in 10 mL of Diluent. Dilute 1.0 mL of this solution with Diluent to 50 mL. Sample solution: 40 mg of Esomeprazole Magnesium in 5 mL of methanol, and dilute with Diluent to 25 mL. Dilute 1 mL of this solution with Diluent to 50 mL. Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 302 nm Column: 4.0-mm × 10-cm; packing L41 Flow rate: 0.6 mL/min Injection size: 20 μL System suitability Sample: System suitability solution Suitability requirements Resolution: NLT 3 between the enantiomer peaks. [NOTE—The elution order is the Renantiomer, followed by the esomeprazole peak, which is the S-enantiomer. ] Analysis rT Name Relative Retention Time Acceptance Criteria, NMT (%) Omeprazole N-oxide a 0.45 0.1 Omeprazole sulfoneb (related compound A) 0.8 0.2 Any other individual impurities — 0.1 Omeprazole 1.0 — a 4-Methoxy-2-[[(RS)-(5-methoxy-1H-benzimidazol-2-yl)sulfinyl]methyl]-3,5- dimethylpyridine 1-oxide. b 5-Methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1Hbenzimidazole. Sample: Sample solution Calculate the percentage of the R-enantiomer in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × 100 Acceptance criteria: NMT 0.2% of the R-enantiomer SPECIFIC TESTS • WATER DETERMINATION, Method I 921 : 6.0%–8.0% • COLOR OF SOLUTION Sample solution: 20 mg/mL of Esomeprazole Magnesium in methanol Analysis: Determine the absorbance of this solution at 440 nm, in 1-cm cells, using methanol as the blank. Acceptance criteria: NMT 0.2 ADDITIONAL REQUIREMENTS • PACKAGING AND STORAGE: Preserve in tight containers, protected from light. Store at room temperature. • USP REFERENCE STANDARDS 11 USP Esomeprazole Magnesium RS USP OMEPRAZOLE RS USP OMEPRAZOLE RELATED COMPOUND A RS Omeprazole sulfone, 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]- 1H-benzimidazole. C17H19N3O4S 361.42 [CAS-88546-55-8]. Auxiliary Information— Please check for your question in the FAQs before contacting USP. USP34–NF29 Page 2741 Pharmacopeial Forum: Volume No. 35(3) Page 550 Chromatographic Column— ESOMEPRAZOLE MAGNESIUM rU = = peak response for the R-enantiomer rS = = sum of the peak responses for esomeprazole and R-enantiomer Topic/Question Contact Expert Committee Monograph Elena Gonikberg, Ph.D. Principal Scientific Liaison 1-301-816-8251 (SM32010) Monographs - Small Molecules 3 Reference Standards RS Technical Services 1-301-816-8129 rstech@usp.org Chromatographic columns text is not derived from, and not part of, USP 34 or NF 29 还有EP7.0里面是三水合物的标准,如果需要可以联系我,或留下邮箱我把标准发给你! |
3楼2011-08-30 14:44:06
4楼2011-08-30 14:50:28










回复此楼
CZX99
